Preparation and evaluation of the cytotoxic nature of TiO2 nanoparticles by direct contact method

采用直接接触法制备和评价TiO2纳米粒子的细胞毒性

阅读:1

Abstract

The purpose of this study is to prepare and evaluate the effect of synthesized titanium dioxide (TiO2) nanoparticles for their biocompatibility on physiological body fluids and the effect of cell toxicity to produce osteointegration when used as implantable materials. For the past few decades, the number of researches done to understand the importance of the biocompatibility of bioceramics, metals, and polymers and their effect on clinical settings of biomedical devices has increased. Hence, the total concept of biocompatibility encourages researchers to actively engage in the investigation of the most compatible materials in living systems by analyzing them using suitable physical, chemical, and biological (bioassay) methods. The ceramic material nano TiO2 was prepared by sol-gel method and analyzed for its functional group and phase formation by Fourier transform infrared spectroscopy and powder X-ray diffraction. Furthermore, the particle size, shape, surface topography, and morphological behavior were analyzed by dynamic light scattering, zeta potential, scanning electron microscopy-energy dispersive X-ray analysis, and transmission electron microscopy analysis. In addition to this, the cytotoxicity and cytocompatibility were determined on MG63 cell lines with varying doses of concentrations such as 1 µg/mL, 10 µg/mL, 25 µg/mL, 50 µg/mL, and 100 µg/mL with different time periods such as 24 hours and 48 hours. The results have not shown any toxicity, whereas, it improved the cell viability/proliferation at various concentrations. Hence, these findings indicate that the nano TiO2 material acts as a good implantable material when used in the biomedical field as a prime surface-modifying agent.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。